MX2021005877A - Compuesto heterociclico. - Google Patents
Compuesto heterociclico.Info
- Publication number
- MX2021005877A MX2021005877A MX2021005877A MX2021005877A MX2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compound
- compound
- cocrystal
- solvate
- prophylactic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101150113681 MALT1 gene Proteins 0.000 abstract 1
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 abstract 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940043274 prophylactic drug Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un compuesto que puede tener el efecto de inhibir MALT1 y se espera que sea útil como fármaco profiláctico o terapéutico para el cáncer, etc. Un compuesto representado por la fórmula (I) [donde cada símbolo es como se define en la descripción], una sal del mismo, o un cocristal, un hidrato o un solvato del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018222530 | 2018-11-28 | ||
| PCT/JP2019/046261 WO2020111087A1 (ja) | 2018-11-28 | 2019-11-27 | 複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005877A true MX2021005877A (es) | 2021-07-16 |
Family
ID=70853784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005877A MX2021005877A (es) | 2018-11-28 | 2019-11-27 | Compuesto heterociclico. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20220048916A1 (es) |
| EP (1) | EP3888652A4 (es) |
| JP (2) | JP6972384B2 (es) |
| KR (2) | KR102646470B1 (es) |
| CN (1) | CN113038948A (es) |
| AU (1) | AU2019390863A1 (es) |
| BR (1) | BR112021009994A2 (es) |
| CA (1) | CA3120774A1 (es) |
| IL (2) | IL303962A (es) |
| MX (1) | MX2021005877A (es) |
| PH (1) | PH12021551251A1 (es) |
| SG (1) | SG11202105652XA (es) |
| TW (2) | TWI784213B (es) |
| WO (1) | WO2020111087A1 (es) |
| ZA (1) | ZA202104402B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3888652A4 (en) * | 2018-11-28 | 2022-10-19 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| JPWO2021241611A1 (es) | 2020-05-27 | 2021-12-02 | ||
| GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| TW202342032A (zh) * | 2022-02-02 | 2023-11-01 | 日商小野藥品工業股份有限公司 | 含有ｍａｌｔ１抑制劑作為有效成分的癌治療劑 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2288521A1 (fr) * | 1974-10-25 | 1976-05-21 | Merck Patent Gmbh | Nouvelles penicillines et procede pour leur preparation |
| KR100399798B1 (ko) * | 1995-05-31 | 2004-05-31 | 스미또모 세이야꾸 가부시키가이샤 | 신규나프티리딘유도체 |
| GB9720052D0 (en) * | 1997-09-19 | 1997-11-19 | Smithkline Beecham Plc | Novel compounds |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| KR20170007311A (ko) | 2014-05-28 | 2017-01-18 | 노파르티스 아게 | 신규 피라졸로 피리미딘 유도체 및 malt1 억제제로서의 그의 용도 |
| CA3003820A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| AU2017302182B2 (en) * | 2016-07-29 | 2021-11-04 | Lupin Limited | Substituted thiazolo-pyridine compounds as MALT1 inhibitors |
| EP3535254A4 (en) | 2016-11-01 | 2020-06-24 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | COMPOUNDS FOR THE DEGRADATION OF MALT1 |
| US11248007B2 (en) * | 2017-03-08 | 2022-02-15 | Cornell University | Inhibitors of MALT1 and uses thereof |
| US20200111087A1 (en) * | 2018-10-08 | 2020-04-09 | Jinlei Zhou | Method for encrypting digital contract document between contractors |
| EP3888652A4 (en) * | 2018-11-28 | 2022-10-19 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
-
2019
- 2019-11-27 EP EP19890558.0A patent/EP3888652A4/en active Pending
- 2019-11-27 CA CA3120774A patent/CA3120774A1/en active Pending
- 2019-11-27 TW TW108143201A patent/TWI784213B/zh active
- 2019-11-27 KR KR1020227003334A patent/KR102646470B1/ko active IP Right Grant
- 2019-11-27 CN CN201980078144.XA patent/CN113038948A/zh active Pending
- 2019-11-27 AU AU2019390863A patent/AU2019390863A1/en active Pending
- 2019-11-27 US US17/296,434 patent/US20220048916A1/en active Pending
- 2019-11-27 MX MX2021005877A patent/MX2021005877A/es unknown
- 2019-11-27 TW TW111139300A patent/TW202306956A/zh unknown
- 2019-11-27 SG SG11202105652XA patent/SG11202105652XA/en unknown
- 2019-11-27 BR BR112021009994-8A patent/BR112021009994A2/pt unknown
- 2019-11-27 IL IL303962A patent/IL303962A/en unknown
- 2019-11-27 WO PCT/JP2019/046261 patent/WO2020111087A1/ja unknown
- 2019-11-27 KR KR1020217019537A patent/KR102359143B1/ko active IP Right Grant
- 2019-11-27 JP JP2020557754A patent/JP6972384B2/ja active Active
-
2021
- 2021-05-23 IL IL283368A patent/IL283368A/en unknown
- 2021-05-28 PH PH12021551251A patent/PH12021551251A1/en unknown
- 2021-06-25 ZA ZA2021/04402A patent/ZA202104402B/en unknown
- 2021-07-02 US US17/367,171 patent/US11230545B2/en active Active
- 2021-11-02 JP JP2021179627A patent/JP7434249B2/ja active Active
- 2021-11-17 US US17/528,677 patent/US11897879B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210332045A1 (en) | 2021-10-28 |
| AU2019390863A1 (en) | 2021-06-24 |
| CN113038948A (zh) | 2021-06-25 |
| TW202039484A (zh) | 2020-11-01 |
| TW202306956A (zh) | 2023-02-16 |
| JP7434249B2 (ja) | 2024-02-20 |
| KR102359143B1 (ko) | 2022-02-08 |
| JPWO2020111087A1 (ja) | 2021-09-27 |
| EP3888652A1 (en) | 2021-10-06 |
| US11897879B2 (en) | 2024-02-13 |
| US20220048916A1 (en) | 2022-02-17 |
| SG11202105652XA (en) | 2021-06-29 |
| KR102646470B1 (ko) | 2024-03-11 |
| US20220089595A1 (en) | 2022-03-24 |
| TWI784213B (zh) | 2022-11-21 |
| WO2020111087A1 (ja) | 2020-06-04 |
| PH12021551251A1 (en) | 2021-12-06 |
| BR112021009994A2 (pt) | 2021-08-17 |
| EP3888652A4 (en) | 2022-10-19 |
| KR20210092301A (ko) | 2021-07-23 |
| JP2022017461A (ja) | 2022-01-25 |
| JP6972384B2 (ja) | 2021-11-24 |
| KR20220019848A (ko) | 2022-02-17 |
| US11230545B2 (en) | 2022-01-25 |
| AU2019390863A2 (en) | 2021-07-01 |
| IL303962A (en) | 2023-08-01 |
| CA3120774A1 (en) | 2020-06-04 |
| IL283368A (en) | 2021-07-29 |
| ZA202104402B (en) | 2023-01-25 |
| WO2020111087A9 (ja) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551251A1 (en) | Heterocyclic compound | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| MX2022011029A (es) | Compuestos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. | |
| PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| MY174821A (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| EA201990833A1 (ru) | Соединение пиридина | |
| SG11201901061QA (en) | Heterocyclic compound | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
| MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| AU2015211852A1 (en) | Heterocyclic sulfonamide derivative and medicine comprising same | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| PH12019502248A1 (en) | Ip6k inhibitors | |
| MX2018014813A (es) | Composiciones antibacterianas. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX2019011182A (es) | Combinacion de derivados de isoindolinona con sgi-110. | |
| EP3838897A3 (en) | (hetero)arylamide compound for inhibiting protein kinase activity | |
| MX2022004713A (es) | Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos. | |
| AU2019296118A8 (en) | Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor |